Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Appears in Networks 1

In-Edges 3

path(MESH:"Amyotrophic Lateral Sclerosis") positiveCorrelation p(HGNC:TARDBP, pmod(HBP:misfolding)) View Subject | View Object

Another common proteinopathy occurs from the misfolding of TARDNA binding protein 43 kDa (TDP-43), which is primarily seen in amyotrophic lateral sclerosis (ALS) and FTD [67] PubMed:29758300

path(MESH:"Frontotemporal Dementia") positiveCorrelation p(HGNC:TARDBP, pmod(HBP:misfolding)) View Subject | View Object

Another common proteinopathy occurs from the misfolding of TARDNA binding protein 43 kDa (TDP-43), which is primarily seen in amyotrophic lateral sclerosis (ALS) and FTD [67] PubMed:29758300

Out-Edges 2

p(HGNC:TARDBP, pmod(HBP:misfolding)) positiveCorrelation path(MESH:"Amyotrophic Lateral Sclerosis") View Subject | View Object

Another common proteinopathy occurs from the misfolding of TARDNA binding protein 43 kDa (TDP-43), which is primarily seen in amyotrophic lateral sclerosis (ALS) and FTD [67] PubMed:29758300

p(HGNC:TARDBP, pmod(HBP:misfolding)) positiveCorrelation path(MESH:"Frontotemporal Dementia") View Subject | View Object

Another common proteinopathy occurs from the misfolding of TARDNA binding protein 43 kDa (TDP-43), which is primarily seen in amyotrophic lateral sclerosis (ALS) and FTD [67] PubMed:29758300

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.